(Q39290307)

10 September 2017

1 reference

title

Metabolic reprogramming in clear cell renal cell carcinoma (English)

1 reference

10 September 2017

Hiromi I Wettersten

1

1 reference

10 September 2017

Omran Abu Aboud

series ordinal

2

1 reference

10 September 2017

Primo N Lara

series ordinal

3

1 reference

10 September 2017

Robert H Weiss

series ordinal

4

1 reference

10 September 2017

language of work or name

English

0 references

publication date

8 May 2017

1 reference

Nature Reviews Nephrology

10 September 2017

published in

1 reference

10 September 2017

volume

13

1 reference

10 September 2017

issue

7

1 reference

10 September 2017

page(s)

410-419

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneph.2017.59

10 September 2017

exact match

0 references

cites work

Oncogenes: Implications for the Diagnosis and Treatment of Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

On the Origin of Cancer Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Kidney cancer: identification of novel targets for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

The Nephrologist's Tumor: Basic Biology and Management of Renal Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Cancer cell metabolism: one hallmark, many faces.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Novel drugs that target the metabolic reprogramming in renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Grade-Dependent Metabolic Reprogramming in Kidney Cancer Revealed by Combined Proteomics and Metabolomics Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

The metabolic basis of kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

The genetic basis of kidney cancer: a metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial sloan-kettering cancer center experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Regulation of the pentose phosphate pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Antioxidants accelerate lung cancer progression in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Glutamine addiction: a new therapeutic target in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

VHL and HIF signalling in renal cell carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Renal cancer in von Hippel-Lindau disease and related syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Grade-dependent proteomics characterization of kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Targeting renal cell carcinoma with a HIF-2 antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

The von Hippel-Lindau tumor suppressor gene and kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Comprehensive molecular characterization of clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Pathway analysis of kidney cancer using proteomics and metabolic profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Serotonin release varies with brain tryptophan levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

T cell apoptosis by tryptophan catabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Cancer metabolism: fatty acid oxidation in the limelight

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Fatty acid synthase, a proficient multifunctional enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Urinary acylcarnitines are altered in human kidney cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

21 January 2018

Biology of HIF-1alpha

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

THE METABOLISM OF TUMORS IN THE BODY

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Metabolic reprogramming: a cancer hallmark even warburg did not anticipate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Cellular Metabolism and Induced Pluripotency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Pyruvate carboxylase is critical for non-small-cell lung cancer proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Fructose-1,6-bisphosphatase opposes renal carcinoma progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Warburg phenotype in renal cell carcinoma: high expression of glucose-transporter 1 (GLUT-1) correlates with low CD8(+) T-cell infiltration in the tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Regulation of cancer cell metabolism by hypoxia-inducible factor 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

HIF-1: upstream and downstream of cancer metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Regulatory Effects of microRNA-92 (miR-92) on VHL Gene Expression and the Hypoxic Activation of miR-210 in Clear Cell Renal Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

miR-210: fine-tuning the hypoxic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Metabolic profiling reveals key metabolic features of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

KEGG: new perspectives on genomes, pathways, diseases and drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

KEGG as a reference resource for gene and protein annotation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

KEGG: kyoto encyclopedia of genes and genomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

The effects of acidosis and alkalosis on the metabolism of glutamine and glutamate in renal cortex slices

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Flux balance analysis predicts essential genes in clear cell renal cell carcinoma metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Arginine metabolism: nitric oxide and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Argininosuccinate synthetase from the urea cycle to the citrulline–NO cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Arginine starvation impairs mitochondrial respiratory function in ASS1-deficient breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Quantitative assessment of tumor metabolism using FDG-PET imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Positron-emission tomography and assessment of cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Regulation of the Warburg effect in early-passage breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Diagnostic Challenges of Kidney Cancer: A Systematic Review of the Role of Positron Emission Tomography-Computerized Tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Efficiency of [(18)F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Clinically significant association between the maximum standardized uptake value on 18F-FDG PET and expression of phosphorylated Akt and S6 kinase for prediction of the biological characteristics of renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Modeling Adult Gliomas Using RCAS/t-va Technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

M1 and M2 Macrophages: Oracles of Health and Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

PET imaging of inflammation biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Adenosine receptor signaling modulates permeability of the blood-brain barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

PET imaging of glutaminolysis in tumors by 18F-(2S,4R)4-fluoroglutamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Real-time imaging of HIF-1alpha stabilization and degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Precision medicine from the renal cancer genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Obesity: The fat advantage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

FASN Inhibition and Taxane Treatment Combine to Enhance Anti-tumor Efficacy in Diverse Xenograft Tumor Models through Disruption of Tubulin Palmitoylation and Microtubule Organization and FASN Inhibition-Mediated Effects on Oncogenic Signaling and G

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Cancer genomics: Spot the difference

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Continued increase in incidence of renal cell carcinoma, especially in young patients and high grade disease: United States 2001 to 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Renal-Cell Cancer--Targeting an Immune Checkpoint or Multiple Kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Prognostic significance of biallelic loss of PTEN in clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Akt stimulates aerobic glycolysis in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Akt mediates mitochondrial protection in cardiomyocytes through phosphorylation of mitochondrial hexokinase-II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Targeting the PI3K-Akt pathway in kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

TIGAR, a p53-inducible regulator of glycolysis and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

p53 pathway in renal cell carcinoma is repressed by a dominant mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Novel mutations and role of the LKB1 gene as a tumor suppressor in renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Underexpression of tumour suppressor LKB1 in clear cell renal cell carcinoma is common and confers growth advantage in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

c-Myc transactivation of LDH-A: implications for tumor metabolism and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Synergy in tumor suppression by direct interaction of Neutral Endopeptidase with PTEN

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Reductive carboxylation supports growth in tumour cells with defective mitochondria.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Inhibiting tryptophan metabolism enhances interferon therapy in kidney cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Fatty acid synthase over expression is an indicator of tumor aggressiveness and poor prognosis in renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Expression of GLUT1 in primary renal tumors: morphologic and biologic implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Inhibitory effect of tumor cell-derived lactic acid on human T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

IDO inhibitors move center stage in immuno-oncology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

Incidence and properties of renal masses and asymptomatic renal cell carcinoma detected by abdominal ultrasonography

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.59

7 January 2021

inferred from DOI database lookup

Molecular imaging of hypoxia-inducible factor 1 alpha and von Hippel-Lindau interaction in mice

1 reference

12 December 2020

Arginine deprivation therapy for malignant melanoma

1 reference

12 December 2020

Mechanism of rat liver microsomal stearyl-CoA desaturase. Studies of the substrate specificity, enzyme-substrate interactions, and the function of lipid

1 reference

12 December 2020

Abnormal cholesterol metabolism in renal clear cell carcinoma

1 reference

12 December 2020

Argininosuccinate synthase: at the center of arginine metabolism

1 reference

12 December 2020

Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.

1 reference

12 December 2020

Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features

1 reference

12 December 2020

Indoleamine 2,3-dioxygenase. Purification and some properties

1 reference

12 December 2020

Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2017.59

1 reference

10 September 2017

1 reference